Drug Trial Radar · NCT05005728
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Oct 22, 2021
Primary completion
Jun 10, 2025
Study completion Jun 10, 2025
Sponsor
- Lead sponsor
- Xencor, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.
Conditions
- Metastatic Castration-Resistant Prostate Cancer
Interventions
vudalimab + carboplatin + cabazitaxelCombination product
Vudalimab IV, carboplatin IV, cabazitaxel IV
vudalimab + olaparibCombination product
Vudalimab IV, olaparib oral
vudalimab monotherapyBiological
Vudalimab IV
vudalimab + docetaxelCombination product
Vudalimab IV, docetaxel IV
vudalimab + cabazitaxel or docetaxelCombination product
Vudalimab IV, cabazitaxel or docetaxel IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab)Time frame: 8 weeks
Locations
26 sites in 1 country. Site status is shown where the registry gives one.
Alaska Oncology and Hematology
Anchorage, Alaska
Palo Verde Hematology Oncology
Glendale, Arizona
Mayo Clinic Hospital
Phoenix, Arizona
City of Hope
Duarte, California
VA Greater Los Angeles
Los Angeles, California
University of California, San Diego
San Diego, California
Rocky Mountain Cancer Centers
Lone Tree, Colorado
Mayo Clinic
Jacksonville, Florida
The University of Chicago Medical Center
Chicago, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
University of Kansas Clinical Research Center
Fairway, Kansas
Mayo Clinic
Rochester, Minnesota
GU Research Network/Urology Cancer Center
Omaha, Nebraska
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
XCancer New Mexico Oncology Hematology Consultants, Ltd.
Albuquerque, New Mexico
Columbia University
New York, New York
Montefiore Medical Center
The Bronx, New York
Northwest Cancer Specialists
Tigard, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Carolina Urologic Research Center
Myrtle Beach, South Carolina
SCRI Oncology Partners
Nashville, Tennessee
Texas Oncology-Central South
Weslaco, Texas
Virginia Cancer Specialists
Fairfax, Virginia
Virginia Oncology Associates
Norfolk, Virginia
University of Washington/Seattle Cancer Care/Alliance
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.